It’s been about 10 years since a new neuromodulator arrived to give patients more options when seeking smoother skin. Now, however, there’s another injectable joining BOTOX® and its fellow botulinum toxin-based muscle relaxers: Jeuveau™. The Los Angeles-based team at Skin Care & Laser Physicians of Beverly Hills was heavily involved in this new cosmetic treatment’s journey to an FDA approval. Dr. Derek Jones, Dr. Naissan Wesley, and Dr. Jeanette Black all served as investigators on the study that ultimately led to the U.S. Food and Drug Administration giving Jeuveau™ the green light for addressing frown lines on the forehead.
Jeuveau™ is unique in the world of neuromodulators, as it was created specifically with aesthetics in mind. While BOTOX® made its way into the hands of cosmetic dermatologists via the medical route, Jeuveau™ is the first such injectable to be considered “aesthetic only.”
Aside from its unique creation story, Jeuveau™ is very similar to BOTOX® in its application, the duration of its effects, and other aspects. It is injected directly into the facial muscles, where it serves to inhibit contractions for months at a time. During this window of forced forehead relaxation, there will be no activity that causes frown lines to appear.
These effects will wear off over time, after which patients can opt for a new round of injections.
Dr. Derek Jones is a renowned Los Angeles and Beverly Hills area dermatologist practicing in cosmetic and general dermatology.